Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Demcizumab |
Trade Name | |
Synonyms | OMP-21M18|anti-delta-like 4 monoclonal antibody OMP-21M18 |
Drug Descriptions |
Demcizumab (OMP-21M18) is a monoclonal antibody that binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation and tumor growth (PMID: 19664991, PMID: 25324140, PMID: 32037195). |
DrugClasses | DLL4 Antibody 7 |
CAS Registry Number | 1243262-17-0 |
NCIT ID | C80041 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Demcizumab + Pemetrexed Disodium | Carboplatin Demcizumab Pemetrexed Disodium | 0 | 0 |
Dasatinib + Demcizumab | Dasatinib Demcizumab | 0 | 0 |
Demcizumab | Demcizumab | 0 | 2 |
Demcizumab + Gemcitabine | Demcizumab Gemcitabine | 0 | 0 |
Demcizumab + Gemcitabine + Nab-paclitaxel | Demcizumab Gemcitabine Nab-paclitaxel | 0 | 1 |
Demcizumab + Paclitaxel | Demcizumab Paclitaxel | 0 | 0 |
Demcizumab + Pembrolizumab | Demcizumab Pembrolizumab | 0 | 1 |